Vladimir R Muzykantov

List of Publications by Year
in descending order

201	13,338	18887 64	32181 105
papers	citations	h-index	g-index

205	205	205	14501
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation. Nature Nanotechnology, 2022, 17, 86-97.	15.6	57
2	Combating Complement's Deleterious Effects on Nanomedicine by Conjugating Complement Regulatory Proteins to Nanoparticles. Advanced Materials, 2022, 34, e2107070.	11.1	20
3	Dual Affinity to RBCs and Target Cells (DART) Enhances Both Organ- and Cell Type-Targeting of Intravascular Nanocarriers. ACS Nano, 2022, 16, 4666-4683.	7.3	24
4	Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE). Journal of Controlled Release, 2022, 344, 50-61.	4.8	49
5	Targeting vascular inflammation through emerging methods and drug carriers. Advanced Drug Delivery Reviews, 2022, 184, 114180.	6.6	17
6	Targeted In Vivo Loading of Red Blood Cells Markedly Prolongs Nanocarrier Circulation. Bioconjugate Chemistry, 2022, 33, 1286-1294.	1.8	13
7	Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. Nature Biomedical Engineering, 2021, 5, 441-454.	11.6	57
8	A numerical study on drug deliveryviamultiscale synergy of cellular hitchhiking onto red blood cells. Nanoscale, 2021, 13, 17359-17372.	2.8	9
9	Highly efficient CD4+ TÂcell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Molecular Therapy, 2021, 29, 3293-3304.	3.7	88
10	Nanotherapeutic-directed approaches to analgesia. Trends in Pharmacological Sciences, 2021, 42, 527-550.	4.0	7
11	Pathologically stiff erythrocytes impede contraction of blood clots. Journal of Thrombosis and Haemostasis, 2021, 19, 1990-2001.	1.9	22
12	Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers. Annual Review of Biomedical Engineering, 2021, 23, 225-248.	5.7	62
13	Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers. Advanced Drug Delivery Reviews, 2021, 178, 113992.	6.6	43
14	Pathologically stiff erythrocytes impede contraction of blood clots: Reply to comment. Journal of Thrombosis and Haemostasis, 2021, 19, 2894-2895.	1.9	0
15	Erythrocytes as carriers of immunoglobulin-based therapeutics. Acta Biomaterialia, 2020, 101, 422-435.	4.1	25
16	Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17727-17736.	3.3	70
17	Target-mediated exposure enhancement: a previously unexplored limit of TMDD. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 411-420.	0.8	1
18	Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics. Pharmaceutics, 2020, 12, 440.	2.0	66

#	Article	IF	Citations
19	Targeting drug delivery in the vascular system: Focus on endothelium. Advanced Drug Delivery Reviews, 2020, 157, 96-117.	6.6	61
20	Molecularly Engineered Nanobodies for Tunable Pharmacokinetics and Drug Delivery. Bioconjugate Chemistry, 2020, 31, 1144-1155.	1.8	20
21	Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the bloodâ€“brain barrier. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3405-3414.	3.3	97
22	Drug Delivery by Red Cells. Blood, 2020, 136, SCI4-SCI4.	0.6	0
23	CRISPR/Cas9-Mediated Genetic Engineering of Hybridomas for Creation of Antibodies that Allow for Site-Specific Conjugation. Methods in Molecular Biology, 2019, 2033, 81-93.	0.4	1
24	Cross-linker-Modulated Nanogel Flexibility Correlates with Tunable Targeting to a Sterically Impeded Endothelial Marker. ACS Nano, 2019, 13, 11409-11421.	7.3	24
25	Endothelial Targeted Strategies to Combat Oxidative Stress: Improving Outcomes in Traumatic Brain Injury. Frontiers in Neurology, 2019, 10, 582.	1.1	27
26	Microphysiological Engineering of Self-Assembled and Perfusable Microvascular Beds for the Production of Vascularized Three-Dimensional Human Microtissues. ACS Nano, 2019, 13, 7627-7643.	7.3	148
27	Stiffness can mediate balance between hydrodynamic forces and avidity to impact the targeting of flexible polymeric nanoparticles in flow. Nanoscale, 2019, 11, 6916-6928.	2.8	15
28	Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 570-580.	1.3	94
29	Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain. Journal of Controlled Release, 2019, 301, 54-61.	4.8	36
30	Ferritin-based drug delivery systems: Hybrid nanocarriers for vascular immunotargeting. Journal of Controlled Release, 2018, 282, 13-24.	4.8	92
31	Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells. Scientific Reports, 2018, 8, 1615.	1.6	83
32	The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series). Pulmonary Circulation, 2018, 8, 1-18.	0.8	12
33	Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9. Scientific Reports, 2018, 8, 1760.	1.6	32
34	Biomimetic microfluidic platform for the quantification of transient endothelial monolayer permeability and therapeutic transport under mimicked cancerous conditions. Biomicrofluidics, 2018, 12, 014101.	1.2	12
35	Ferritin Nanocages with Biologically Orthogonal Conjugation for Vascular Targeting and Imaging. Bioconjugate Chemistry, 2018, 29, 1209-1218.	1.8	32
36	Targeting therapeutics to endothelium: are we there yet?. Drug Delivery and Translational Research, 2018, 8, 883-902.	3.0	49

#	Article	IF	Citations
37	Targeting superoxide dismutase to endothelial caveolae profoundly alleviates inflammation caused by endotoxin. Journal of Controlled Release, 2018, 272, 1-8.	4.8	47
38	Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting. Bioconjugate Chemistry, 2018, 29, 56-66.	1.8	26
39	Vascular Targeting of Radiolabeled Liposomes with Bio-Orthogonally Conjugated Ligands: Single Chain Fragments Provide Higher Specificity than Antibodies. Bioconjugate Chemistry, 2018, 29, 3626-3637.	1.8	38
40	Spatially controlled assembly of affinity ligand and enzyme cargo enables targeting ferritin nanocarriers to caveolae. Biomaterials, 2018, 185, 348-359.	5.7	49
41	PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. Journal of Controlled Release, 2018, 291, 106-115.	4.8	106
42	Biocompatible coupling of therapeutic fusion proteins to human erythrocytes. Blood Advances, 2018, 2, 165-176.	2.5	42
43	Flexible Nanoparticles Reach Sterically Obscured Endothelial Targets Inaccessible to Rigid Nanoparticles. Advanced Materials, 2018, 30, e1802373.	11.1	73
44	Unintended effects of drug carriers: Big issues of small particles. Advanced Drug Delivery Reviews, 2018, 130, 90-112.	6.6	51
45	Vascular Immunotargeting: Take the Highway to the First Exit. Hepatology, 2018, 68, 1672-1674.	3.6	4
46	Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nature Communications, 2018, 9, 2684.	5.8	247
47	Targeting vascular (endothelial) dysfunction. British Journal of Pharmacology, 2017, 174, 1591-1619.	2.7	355
48	Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1495-1506.	1.7	34
49	Acute administration of catalase targeted to ICAM-1 attenuates neuropathology in experimental traumatic brain injury. Scientific Reports, 2017, 7, 3846.	1.6	56
50	Up-regulation of NADPH oxidase-mediated redox signaling contributes to the loss of barrier function in KRIT1 deficient endothelium. Scientific Reports, 2017, 7, 8296.	1.6	51
51	Superoxide Dismutaseâ€Loaded Porous Polymersomes as Highly Efficient Antioxidants for Treating Neuropathic Pain. Advanced Healthcare Materials, 2017, 6, 1700500.	3.9	41
52	Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemiaâ€reperfusion injury. FASEB Journal, 2017, 31, 761-770.	0.2	27
53	Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond. Transfusion Medicine Reviews, 2017, 31, 26-35.	0.9	67
54	ICAM-1â€“targeted thrombomodulin mitigates tissue factorâ€“driven inflammatory thrombosis in a human endothelialized microfluidic model. Blood Advances, 2017, 1, 1452-1465.	2.5	26

#	Article	IF	Citations
55	Fluorescence Microscopy Imaging Calibration for Quantifying Nanocarrier Binding to Cells During Shear Flow Exposure. Journal of Biomedical Nanotechnology, 2017, 13, 737-745.	0.5	6
56	Mechanism of Collaborative Enhancement of Binding of Paired Antibodies to Distinct Epitopes of Platelet Endothelial Cell Adhesion Molecule-1. PLoS ONE, 2017, 12, e0169537.	1.1	11
57	Biomimetic channel modeling local vascular dynamics of pro-inflammatory endothelial changes. Biomicrofluidics, 2016, 10, 014101.	1.2	36
58	Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugates. Journal of Controlled Release, 2016, 234, 115-123.	4.8	41
59	Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. Advanced Drug Delivery Reviews, 2016, 106, 88-103.	6.6	273
60	Molecular engineering of high affinity single-chain antibody fragment for endothelial targeting of proteins and nanocarriers in rodents and humans. Journal of Controlled Release, 2016, 226, 229-237.	4.8	29
61	Biophysically inspired model for functionalized nanocarrier adhesion to cell surface: roles of protein expression and mechanical factors. Royal Society Open Science, 2016, 3, 160260.	1.1	26
62	Drug delivery by erythrocytes: â€œPrimum non nocereâ€• Transfusion and Apheresis Science, 2016, 55, 275-280.	0.5	37
63	Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles. Bioconjugate Chemistry, 2016, 27, 628-637.	1.8	28
64	Non-affinity factors modulating vascular targeting of nano- and microcarriers. Advanced Drug Delivery Reviews, 2016, 99, 97-112.	6.6	65
65	The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells. PLoS ONE, 2016, 11, e0152074.	1.1	90
66	The Role of Carrier Geometry in Overcoming Biological Barriers to Drug Delivery. Current Pharmaceutical Design, 2016, 22, 1259-1273.	0.9	11
67	Erythrocyte Rigidity Affects Blood Clot Contraction and Formation of Polyhedrocytes. Blood, 2016, 128, 3814-3814.	0.6	2
68	Simultaneous Replacement of Endothelial Thrombomodulin and Plasma Protein C: A Novel Therapeutic Strategy for Sepsis-Induced Disseminated Intravascular Coagulation. Blood, 2016, 128, 2613-2613.	0.6	0
69	Coupling Therapeutics to Human Erythrocytes Demonstrates Target-Dependent Effects on Red Cell Physiology While Preserving Efficacy. Blood, 2016, 128, 701-701.	0.6	0
70	Systems approaches to design of targeted therapeutic delivery. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 253-265.	6.6	7
71	Flow shear stress differentially regulates endothelial uptake of nanocarriers targeted to distinct epitopes of PECAM-1. Journal of Controlled Release, 2015, 210, 39-47.	4.8	49
72	Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: Synergy between physical, chemical and biological approaches. Biomaterials, 2015, 68, 1-8.	5.7	76

#	Article	IF	Citations
73	Collaborative Enhancement of Endothelial Targeting of Nanocarriers by Modulating Platelet-Endothelial Cell Adhesion Molecule-1/CD31 Epitope Engagement. ACS Nano, 2015, 9, 6785-6793.	7.3	22
74	Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect. FASEB Journal, 2015, 29, 3483-3492.	0.2	25
75	Targeted endothelial nanomedicine for common acute pathological conditions. Journal of Controlled Release, 2015, 219, 576-595.	4.8	39
76	Long-circulating Janus nanoparticles made by electrohydrodynamic co-jetting for systemic drug delivery applications. Journal of Drug Targeting, 2015, 23, 750-758.	2.1	31
77	Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier. Therapeutic Delivery, 2015, 6, 795-826.	1.2	91
78	A Microfluidic Model of Microvascular Inflammation: Characterization and Testing of Endothelial-Targeted Therapeutics. Blood, 2015, 126, 3454-3454.	0.6	1
79	Thrombomodulin Fusion Proteins Coupled to Human Erythrocytes Demonstrate Anti-Thrombotic and Anti-Inflammatory Activity. Blood, 2015, 126, 3493-3493.	0.6	0
80	Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer Biology and Therapy, 2014, 15, 443-451.	1.5	20
81	Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials, 2014, 35, 3708-3715.	5.7	80
82	Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. Journal of Controlled Release, 2014, 177, 34-41.	4.8	86
83	Vascular Targeting of Nanocarriers: Perplexing Aspects of the Seemingly Straightforward Paradigm. ACS Nano, 2014, 8, 4100-4132.	7.3	154
84	Nanocarriers for Vascular Delivery of Anti-Inflammatory Agents. Annual Review of Pharmacology and Toxicology, 2014, 54, 205-226.	4.2	85
85	Targeting to Endothelial Cells Augments the Protective Effect of Novel Dual Bioactive Antioxidant/Anti-Inflammatory Nanoparticles. Molecular Pharmaceutics, 2014, 11, 2262-2270.	2.3	23
86	Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin. Journal of Nuclear Medicine, 2014, 55, 500-507.	2.8	28
87	ICAM-1 Targeted Nanogels Loaded with Dexamethasone Alleviate Pulmonary Inflammation. PLoS ONE, 2014, 9, e102329.	1.1	68
88	Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget, 2014, 5, 6994-7012.	0.8	14
89	Delivering Nanoparticles to Lungs while Avoiding Liver and Spleen through Adsorption on Red Blood Cells. ACS Nano, 2013, 7, 11129-11137.	7.3	276
90	Drug delivery carriers on the fringes: natural red blood cells versus synthetic multilayered capsules. Expert Opinion on Drug Delivery, 2013, 10, 1-4.	2.4	35

#	Article	IF	Citations
91	Reduction of Nanoparticle Avidity Enhances the Selectivity of Vascular Targeting and PET Detection of Pulmonary Inflammation. ACS Nano, 2013, 7, 2461-2469.	7.3	94
92	Nanocarrier Hydrodynamics and Binding in Targeted Drug Delivery: Challenges in Numerical Modeling and Experimental Validation. Journal of Nanotechnology in Engineering and Medicine, 2013, 4, 101011-1010115.	0.8	26
93	Targeted Drug Delivery to Endothelial Adhesion Molecules. ISRN Vascular Medicine, 2013, 2013, 1-27.	0.7	33
94	Platelet Endothelial Cell Adhesion Molecule Targeted Oxidant-Resistant Mutant Thrombomodulin Fusion Protein with Enhanced Potency In Vitro and In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 339-345.	1.3	19
95	Assessment of protein binding with magnetic microrobots in fluid. , 2013, , .		5
96	Vascular Immunotargeting to Endothelial Determinant ICAM-1 Enables Optimal Partnering of Recombinant scFv-Thrombomodulin Fusion with Endogenous Cofactor. PLoS ONE, 2013, 8, e80110.	1.1	48
97	Anti-Inflammatory Effect of Targeted Delivery of SOD to Endothelium: Mechanism, Synergism with NO Donors and Protective Effects In Vitro and In Vivo. PLoS ONE, 2013, 8, e77002.	1.1	50
98	Detecting cell adhesion molecules in intact lung using quantum dot conjugates targeted to endothelial cells. FASEB Journal, 2013, 27, 1143.3.	0.2	0
99	Dynamic Factors Controlling Targeting Nanocarriers to Vascular Endothelium. Current Drug Metabolism, 2012, 13, 70-81.	0.7	27
100	The shape of things to come: importance of design in nanotechnology for drug delivery. Therapeutic Delivery, 2012, 3, 181-194.	1.2	209
101	Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities. Science, 2012, 338, 903-910.	6.0	1,166
102	Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo. Journal of Controlled Release, 2012, 163, 161-169.	4.8	71
103	Acute and Chronic Shear Stress Differently Regulate Endothelial Internalization of Nanocarriers Targeted to Platelet-Endothelial Cell Adhesion Molecule-1. ACS Nano, 2012, 6, 8824-8836.	7.3	98
104	Targeted interception of signaling reactive oxygen species in the vascular endothelium. Therapeutic Delivery, 2012, 3, 263-276.	1.2	37
105	Microthrombosis after experimental subarachnoid hemorrhage: Time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan. Experimental Neurology, 2012, 233, 357-363.	2.0	65
106	Endothelial targeting of polymeric nanoparticles stably labeled with the PET imaging radioisotope iodine-124. Biomaterials, 2012, 33, 5406-5413.	5.7	75
107	Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. Journal of Controlled Release, 2012, 157, 485-492.	4.8	91
108	Collaborative Enhancement of Antibody Binding to Distinct PECAM-1 Epitopes Modulates Endothelial Targeting. PLoS ONE, 2012, 7, e34958.	1.1	30

#	Article	IF	Citations
109	Peptide Quantum Dot Conjugates Detect Integrin Î± v Î² 3. FASEB Journal, 2012, 26, .	0.2	0
110	Iron Oxide Nanoparticles Are Less Toxic to Endothelial Cells When Coated With Dextran and Polyethylene Glycol. , 2011, , .		0
111	Endothelial Targeting of Antibody-Decorated Polymeric Filomicelles. ACS Nano, 2011, 5, 6991-6999.	7.3	102
112	Targeted Endothelial Delivery of Nanosized Catalase Immunoconjugates Protects Lung Grafts Donated After Cardiac Death. Transplantation, 2011, 92, 380-387.	0.5	29
113	Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig. Pediatric Critical Care Medicine, 2011, 12, e369-e375.	0.2	20
114	Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent. Blood, 2011, 117, 4964-4967.	0.6	32
115	Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. Journal of Controlled Release, 2011, 150, 37-44.	4.8	73
116	Modulation of endothelial targeting by size of antibodyâ€“antioxidant enzyme conjugates. Journal of Controlled Release, 2011, 149, 236-241.	4.8	51
117	Targeted modulation of reactive oxygen species in the vascular endothelium. Journal of Controlled Release, 2011, 153, 56-63.	4.8	50
118	Targeted nanocarriers for imaging and therapy of vascular inflammation. Current Opinion in Colloid and Interface Science, 2011, 16, 215-227.	3.4	67
119	Targeted therapeutics and nanodevices for vascular drug delivery: Quo vadis?. IUBMB Life, 2011, 63, 583-585.	1.5	11
120	Nanocarriers for vascular delivery of antioxidants. Nanomedicine, 2011, 6, 1257-1272.	1.7	90
121	Catalase and Superoxide Dismutase Conjugated with Platelet-Endothelial Cell Adhesion Molecule Antibody Distinctly Alleviate Abnormal Endothelial Permeability Caused by Exogenous Reactive Oxygen Species and Vascular Endothelial Growth Factor. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 82-91.	1.3	66
122	PECAMâ€targeted delivery of SOD inhibits endothelial inflammatory response. FASEB Journal, 2011, 25, 348-357.	0.2	89
123	Targeting delivery of drugs in the vascular system. International Journal of Transport Phenomena, 2011, 12, 41-49.	0.0	15
124	Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. Journal of Controlled Release, 2010, 146, 144-151.	4.8	104
125	NO gets a test ride on high-tech transporting nanodevices: A commentary on â€œSustained-release nitric oxide from long-lived circulating nanoparticlesâ€• Free Radical Biology and Medicine, 2010, 49, 528-529.	1.3	4
126	Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16530-16535.	3.3	116

#	Article	IF	Citations
127	Targeting Antioxidant and Antithrombotic Biotherapeutics to Endothelium. Seminars in Thrombosis and Hemostasis, 2010, 36, 332-342.	1.5	20
128	Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opinion on Drug Delivery, 2010, 7, 403-427.	2.4	323
129	Synthesis and Characterization of Polymer Nanocarriers for the Targeted Delivery of Therapeutic Enzymes. Methods in Molecular Biology, 2010, 610, 145-164.	0.4	13
130	Erythrocyte-Bound Tissue Plasminogen Activator is Neuroprotective in Experimental Traumatic Brain Injury. Journal of Neurotrauma, 2009, 26, 1585-1592.	1.7	37
131	Targeted Detoxification of Selected Reactive Oxygen Species in the Vascular Endothelium. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 404-411.	1.3	70
132	Chair's Summary. Proceedings of the American Thoracic Society, 2009, 6, 398-402.	3.5	13
133	Anchoring Fusion Thrombomodulin to the Endothelial Lumen Protects against Injury-induced Lung Thrombosis and Inflammation. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 247-256.	2.5	55
134	Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. Journal of Controlled Release, 2009, 139, 190-196.	4.8	52
135	How I became a biochemistÃ¢Â€Â”from Moscow to Philadelphia, by way of Charlottesville: A story of one Wood/Whelan fellowship journey. IUBMB Life, 2009, 62, NA-NA.	1.5	0
136	Targeted delivery of therapeutics to endothelium. Cell and Tissue Research, 2009, 335, 283-300.	1.5	100
137	Loading PEG-Catalase into Filamentous and Spherical Polymer Nanocarriers. Pharmaceutical Research, 2009, 26, 250-260.	1.7	35
138	Red Blood Cells-Coupled tPA Prevents Impairment of Cerebral Vasodilatory Responses and Tissue Injury in Pediatric Cerebral Hypoxia/Ischemia through Inhibition of ERK MAPK Activation. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1463-1474.	2.4	36
139	Filamentous Polymer Nanocarriers of Tunable Stiffness that Encapsulate the Therapeutic Enzyme Catalase. Biomacromolecules, 2009, 10, 1324-1330.	2.6	39
140	Flow dynamics, binding and detachment of spherical carriers targeted to ICAM-1 on endothelial cells. Biorheology, 2009, 46, 323-341.	1.2	59
141	Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials, 2008, 29, 215-227.	5.7	105
142	Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. Journal of Controlled Release, 2008, 130, 226-233.	4.8	71
143	Polymeric carriers: role of geometry in drug delivery. Expert Opinion on Drug Delivery, 2008, 5, 1283-1300.	2.4	175
144	In Vivo Imaging of⁶⁴Cu-Labeled Polymer Nanoparticles Targeted to the Lung Endothelium. Journal of Nuclear Medicine, 2008, 49, 103-111.	2.8	120

#	Article	IF	Citations
145	Control of Endothelial Targeting and Intracellular Delivery of Therapeutic Enzymes by Modulating the Size and Shape of ICAM-1-targeted Carriers. Molecular Therapy, 2008, 16, 1450-1458.	3.7	506
146	Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator. Circulation, 2008, 118, 1442-1449.	1.6	77
147	Delivery of Acid Sphingomyelinase in Normal and Niemann-Pick Disease Mice Using Intercellular Adhesion Molecule-1-Targeted Polymer Nanocarriers. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 400-408.	1.3	97
148	Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood, 2008, 111, 1999-2006.	0.6	46
149	The Glycocalyx Protects Erythrocyte-Bound Tissue-Type Plasminogen Activator from Enzymatic Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 158-164.	1.3	44
150	Delivery of Anti-Platelet-Endothelial Cell Adhesion Molecule Single-Chain Variable Fragment-Urokinase Fusion Protein to the Cerebral Vasculature Lyses Arterial Clots and Attenuates Postischemic Brain Edema. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 947-952.	1.3	45
151	Platelet-Endothelial Cell Adhesion Molecule-1-Directed Endothelial Targeting of Superoxide Dismutase Alleviates Oxidative Stress Caused by Either Extracellular or Intracellular Superoxide. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 450-457.	1.3	51
152	Effect of Polymer Amphiphilicity on Loading of a Therapeutic Enzyme into Protective Filamentous and Spherical Polymer Nanocarriers. Biomacromolecules, 2007, 8, 3914-3921.	2.6	54
153	Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium. Journal of Controlled Release, 2007, 118, 235-244.	4.8	31
154	Antioxidant Strategies in Respiratory Medicine. Treatments in Respiratory Medicine, 2006, 5, 47-78.	1.4	109
155	Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Molecular Therapy, 2006, 13, 135-141.	3.7	113
156	Human complement receptor type 1â€“directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood, 2006, 108, 1895-1902.	0.6	60
157	Nanoscale Antioxidant Therapeutics. , 2006, , 1023-1043.		6
158	Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L809-L817.	1.3	66
159	Endothelial Targeting of High-Affinity Multivalent Polymer Nanocarriers Directed to Intercellular Adhesion Molecule 1. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1161-1169.	1.3	176
160	Advanced Drug Delivery Systems That Target The Vascular Endothelium. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 98-112.	3.4	147
161	Specificity and sizeâ€dependence of immunotargeting of the antiâ€PECAM/catalase conjugates to endothelium. FASEB Journal, 2006, 20, A1180.	0.2	0
162	Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood, 2005, 106, 4191-4198.	0.6	66

#	Article	IF	Citations
163	ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood, 2005, 105, 650-658.	0.6	134
164	Polymer nanocarriers protecting active enzyme cargo against proteolysis. Journal of Controlled Release, 2005, 102, 427-439.	4.8	99
165	Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opinion on Drug Delivery, 2005, 2, 909-926.	2.4	81
166	Blood Clearance and Activity of Erythrocyte-Coupled Fibrinolytics. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 1106-1113.	1.3	71
167	Coupling Tissue Type Plasminogen Activator to Carrier Erythrocyte Protects Against Plasma Inhibitors.. Blood, 2005, 106, 1881-1881.	0.6	0
168	Characterization of Endothelial Internalization and Targeting of Antibodyâ€“Enzyme Conjugates in Cell Cultures and in Laboratory Animals. , 2004, 283, 021-036.		25
169	Streptavidinâ€“Biotin Crosslinking of Therapeutic Enzymes With Carrier Antibodies: Nanoconjugates for Protection Against Endothelial Oxidative Stress. , 2004, 283, 003-020.		34
170	Endothelial Endocytic Pathways: Gates for Vascular Drug Delivery. Current Vascular Pharmacology, 2004, 2, 281-299.	0.8	104
171	Pecam-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide. Free Radical Biology and Medicine, 2003, 34, 1035-1046.	1.3	37
172	Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nature Biotechnology, 2003, 21, 392-398.	9.4	139
173	Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nature Biotechnology, 2003, 21, 891-896.	9.4	168
174	Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. American Journal of Physiology - Cell Physiology, 2003, 285, C1339-C1347.	2.1	142
175	A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. Journal of Cell Science, 2003, 116, 1599-1609.	1.2	278
176	PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 285, L283-L292.	1.3	81
177	ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood, 2003, 101, 3977-3984.	0.6	107
178	Platelet-Endothelial Cell Adhesion Molecule-1-Directed Immunotargeting to Cardiopulmonary Vasculature. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 777-786.	1.3	61
179	Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood, 2002, 99, 912-922.	0.6	99
180	Vascular Immunotargeting of Glucose Oxidase to the Endothelial Antigens Induces Distinct Forms of Oxidant Acute Lung Injury. American Journal of Pathology, 2002, 160, 1155-1169.	1.9	55

#	Article	IF	Citations
181	Delivery of Antioxidant Enzyme Proteins to the Lung. Antioxidants and Redox Signaling, 2001, 3, 39-62.	2.5	56
182	Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L1335-L1347.	1.3	116
183	Oxidative burst and NO generation as initial response to ischemia in flow-adapted endothelial cells. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H2126-H2135.	1.5	65
184	Targeting of superoxide dismutase and catalase to vascular endothelium. Journal of Controlled Release, 2001, 71, 1-21.	4.8	162
185	Cellâ€selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting. FASEB Journal, 2001, 15, 416-426.	0.2	57
186	Immunotargeting of glucose oxidase: intracellular production of H₂O₂and endothelial oxidative stress. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L271-L281.	1.3	18
187	In SituImaging of Intracellular Calcium with Ischemia in Lung Subpleural Microvascular Endothelial Cells. Antioxidants and Redox Signaling, 1999, 1, 145-154.	2.5	31
188	Modulation of angiotensin-converting enzyme in cultured human vascular endothelial cells. In Vitro Cellular and Developmental Biology - Animal, 1998, 34, 545-554.	0.7	38
189	Immunotargeting of drugs to the pulmonary vascular endothelium as a therapeutic strategy. Pathophysiology, 1998, 5, 15-33.	1.0	25
190	Epitope-Dependent Selective Targeting of Thrombomodulin Monoclonal Antibodies to Either Surface or Intracellular Compartment of Endothelial Cells. Drug Delivery, 1998, 5, 197-206.	2.5	7
191	Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 275, L806-L817.	1.3	56
192	Target-sensitive immunoerythrocytes: interaction of biotinylated red blood cells with immobilized avidin induces their lysis by complement. Biochimica Et Biophysica Acta - Biomembranes, 1996, 1279, 137-143.	1.4	17
193	Regulation of the Complement-Mediated Elimination of Red Blood Cells Modified with Biotin and Streptavidin. Analytical Biochemistry, 1996, 241, 109-119.	1.1	55
194	Avidin attachment to biotinylated amino groups of the erythrocyte membrane eliminates homologous restriction of both classical and alternative pathways of the complement. FEBS Letters, 1993, 318, 108-112.	1.3	20
195	Avidin attachment to red blood cells via a phoshpolipid derivative of biotin provides complement-resistant immunoerythrocytes. Journal of Immunological Methods, 1993, 158, 183-190.	0.6	29
196	Avidin-induced lysis of biotinylated erythrocytes by homologous complement via the alternative pathway depends on avidin's ability of multipoint binding with biotinylated membrane. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1107, 119-125.	1.4	19
197	Systemic administration of platelet-activating factor in rat reduces specific pulmonary uptake of circulating monoclonal antibody to angiotensin-converting enzyme. Lung, 1992, 170, 349-58.	1.4	19
198	Streptavidin-induced lysis of homologous biotinylated erythrocytes Evidence against the key role of the avidin charge in complement activation via the alternative pathway. FEBS Letters, 1991, 280, 112-114.	1.3	22

#	Article	IF	Citations
199	Immunotargeting of erythrocytes-bound streptokinase provides local lysis of a fibrin clot. Biochimica Et Biophysica Acta - General Subjects, 1986, 884, 355-362.	1.1	47
200	Drug Targeting to Endothelium. , 0, , 1734-1746.		0
201	Targeted Delivery of Biotherapeutics to the Pulmonary Endothelium. , 0, , 355-377.		0